Table 2.
Patient, disease, and treatment characteristics by low vs. high-CTRA gene expression profile
| A | B | C | D |
|---|---|---|---|
| High CTRA (%) | Low CTRA (%) | p-value | |
| Age, median (range), years | 37 (21–59) | 44 (21–59) | 0.04 |
| Age | 0.16 | ||
| 20–29 | 10 (26) | 6 (15) | |
| 30–39 | 13 (33) | 7 (18) | |
| 40–49 | 11 (28) | 18 (46) | |
| 50–59 | 5 (13) | 8 (21) | |
| Sex | 0.65 | ||
| Male | 18 (46) | 20 (52) | |
| Female | 21 (54) | 19 (48) | |
| Median income, 2000* | 32300 | 58257 | 0.02 |
| Distance to transplant center | 0.58 | ||
| <17 miles | 12 (33) | 9 (23) | |
| 17–55 miles | 7 (18) | 12 (33) | |
| 55–150 miles | 11 (28) | 9 (23) | |
| >150 miles | 9 (23) | 9 (23) | |
| KPS | 0.38 | ||
| >=90 | 33 (84) | 28 (72) | |
| <90 | 4 (10) | 6 (16) | |
| Missing | 2 (6) | 5 (12) | |
| Comorbid conditions | 0.17 | ||
| No | 24 (62) | 18 (46) | |
| Yes | 15 (38) | 21 (54) | |
| BMI, median (range), kg/m^2 | 27 (18–51) | 26 (20–44) | 0.9 |
| BMI, kg/m^2 | 0.68 | ||
| 0 < 18.5 | 2 (5) | 0 (0) | |
| 18.5 – 24.9 | 13 (33) | 12 (30) | |
| 25 – 29.9 | 16 (41) | 17 (44) | |
| >=30 | 8 (21) | 10 (26) | |
| SES | |||
| High | 14 (36) | 25 (64) | 0.02 |
| Low | 25 (64) | 14 (36) | |
| Cytogenetics | 0.64 | ||
| Good risk | 0 (0) | 1 (2) | |
| Intermediate risk | 19 (48) | 18 (46) | |
| Poor/adverse risk | 9 (24) | 12 (30) | |
| Unknown | 11 (28) | 8 (20) | |
| HLA match status | 0.95 | ||
| Well matched | 23 (59) | 24 (62) | |
| Partially matched | 10 (26) | 10 (26) | |
| Mismatched | 6 (15) | 5 (13) | |
| Race match (donor/recipient) | 0.87 | ||
| Match | 32 (82) | 32 (82) | |
| Mismatch | 3 (8) | 4 (10) | |
| Unknown | 4 (10) | 3 (8) | |
| Donor age, median (range), years | 37 (20–56) | 35 (21–56) | 0.97 |
| Donor age at transplant, years | 0.48 | ||
| 18–29 | 14 (36) | 11 (28) | |
| 30–39 | 11 (28) | 17 (44) | |
| 40–49 | 10 (26) | 6 (15) | |
| >=50 | 4 (10) | 5 (13) | |
| Sex match (donor/recipient) | 0.78 | ||
| Male/male | 13 (33) | 14 (36) | |
| Male/female | 13 (33) | 9 (23) | |
| Female/male | 5 (13) | 6 (15) | |
| Female/female | 8 (21) | 10 (26) | |
| CMV match (donor/recipient) | 0.71 | ||
| Negative/negative | 14 (36) | 12 (33) | |
| Negative/positive | 11 (28) | 14 (36) | |
| Positive/negative | 6 (15) | 4 (10) | |
| Positive/positive | 7 (18) | 9 (23) | |
| Unknown | 1 (3) | 0 (0) | |
| Year of transplant | 0.64 | ||
| 1995–1999 | 15 (38) | 13 (33) | |
| 2000–2004 | 24 (62) | 26 (67) | |
| Conditioning regimen | 0.74 | ||
| Bu + Cy +/− Other | 5 (12) | 7 (18) | |
| Cy + TBI +/− other | 28 (72) | 26 (67) | |
| TBI +/− other | 3 (8) | 1 (3) | |
| Flu +/− other | 3 (8) | 4 (10) | |
| Other | 0 (0) | 1 (3) | |
| GVHD prophylaxis | 0.84 | ||
| T-cell depletion | 7 (18) | 6 (15) | |
| CSA + MTX +/− others | 17 (44) | 14 (36) | |
| CSA +/− others | 1 (3) | 1 (3) | |
| Tacrolimus + MTX | 12 (31) | 13 (33) | |
| Tacrolimus | 2 (5) | 5 (12) | |
| Graft type | 0.31 | ||
| Bone marrow | 30 (77) | 26 (67) | |
| Peripheral blood | 9 (31) | 13 (33) | |
| Infused BM cell dose | 0.41 | ||
| > 2 × 10^8 | 14 (47) | 15 (58) | |
| <= 2 × 10^8 | 16 (53) | 11 (42) | |
| Missing | 0 (0) | 0 (0) | |
| Infused PB cell dose | 0.02 | ||
| > 5 × 10^8 | 4 (44) | 11 (85) | |
| <= 5 × 10^8 | 4 (44) | 0 (0) | |
| Missing | 1 (11) | 2 (15) | |
| Time from diagnosis to transplant, median (range), months | 6 (3–17) | 5 (3–15) | 0.28 |
| Donor search time, median (range), months | |||
| Diagnosis to preliminary search | 2 (<1–10) | 2 (<1–10) | 0.45 |
| Preliminary search to formal search | <1 (0–12) | <1 (0–3) | 0.44 |
| Formal search to transplant | 3 (2–8) | 3 (2–11) | 0.45 |
| Follow-up of survivors, median (range), months | 28 (12–81) | 36 (23–132) | 0.52 |
| Cause of Death | 0.18 | ||
| Infection | 5 (13) | 5 (13) | |
| Interstitial pneumonia | 3 (8) | 3 (8) | |
| aGVHD | 3 (8) | 4 (10) | |
| Recurrence or persistence of primary disease | 8 (21) | 1 (3) | |
| Organ failure | 5 (13) | 5 (13) | |
| Hemorrhage | 3 (8) | 1 (3) | |
| Other | 12 (31) | 20 (51) |
BM, bone marrow; Bu, busulfan; CMV, cytomegalovirus; CSA, cyclosporine; CTRA, conserved transcriptional response to adversity; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; KPS, Karnofsky Performance Status; MTX, methotrexate; PB, peripheral blood; TBI, total body irradiation
*
Based on 2004 Census tract data linking income to residential ZIP code.